The human RON and its mouse homologue stk are members of the MET family of tyrosine kinase receptors. We have previously shown that the RON gene is over-expressed in human breast carcinomas. As cat mammary tumours have been proposed as a suitable model for aggressive human breast cancer, we identi®ed the feline stk gene and studied its expression in cat mammary cancer. Feline stk sequences were found highly homologous to the stk and RON gene exons that encode the juxtamembrane and transmembrane domains of the stk and RON receptors. Feline stk-speci®c transcript was detected by RT ± PCR in cat lung and in 7/8 feline mammary carcinomas and a synchronous skin metastasis examined. Western blot and immunohistochemical analyses were carried out with an antibody that recognized both the human RON and mouse stk receptors. This antibody speci®cally detected a 135 Kd feline protein and stained 10/34 mammary carcinoma archival samples. These data show that the pattern of expression and distribution of the stk protein in feline mammary cancer could be superimposed on that of the RON receptor in human breast cancer and suggest that these feline tumours are a suitable model to test innovative approaches to therapy of aggressive human breast carcinomas. Oncogene (2002) 21, 1785 ± 1790. DOI: 10.1038/sj/ onc/1205221
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Keywords: tyrosine kinase receptors; mammary carcinomas; companion animals tumours Spontaneous tumours in companion animals oer a unique opportunity as models of human cancer. The relatively high incidence of some cancers, large body size and shorter overall lifespan are factors that contribute to the advantage of these models. Above all, in most cases histopathology and comparable responses to the cytotoxic agents make tumours in companion animals useful to test new therapeutic approaches like new chemotherapeutic regimens, gene therapy and biological modi®cations. However, to date only fragmentary information is available on molecular alterations and biological behaviour of companion animal tumours.
In cats, mammary cancer is a frequent neoplasm (%10% all cases, 17% for females), the most common after lympho-hematopoietic and skin tumours. On the basis of age incidence, histopathology and pattern of metastasis, feline mammary cancer (FMC) could be a good comparative model of human breast cancer (for a review see Weijer et al., 1972) . In particular, the lack of estrogen dependency in most tumours (De las Mulas et al., 2000) may indicate that FMC is a suitable animal model for human hormonal-unresponsive breast cancer. The ®nding of over-expression and ampli®cation of cyclin A (Murakami et al., 2000a) and p53 nuclear accumulation (Murakami et al., 2000b) suggests also a similar tumorigenesis.
Over-expression of tyrosine kinase oncogenes has been reported in many carcinomas (for a review see Kolibaba and Druker, 1997) . In vitro and in vivo studies suggested that among these receptors, those of the MET family might be speci®cally involved in the activation of the tyrosine kinase cascade that stimulates invasive properties of carcinoma cells. The MET gene family members encode the human MET, the mouse met, the human RON and its mouse homologue receptor stk. MET and RON, and their mouse homologues, are the receptors for the Hepatocyte Growth Factor (HGF) and for the Macrophage Stimulating Protein (MSP), respectively. These receptors share biochemical and structural features and biological properties: they mediate proliferation signals but also motility, invasion and protection from apoptosis in physiological and pathological conditions (for a review see Tamagnone and Comoglio, 1997) . Oncogene (2002) We have shown that the MET gene, expressed in several normal human epithelial tissues (Di Renzo et al., 1991; Prat et al., 1991) , is often over-expressed in carcinomas of speci®c histotypes (Di Renzo et al., 1995a,b) . Germline and somatic missense mutations in the MET proto-oncogene have been identi®ed in human hereditary papillary renal cell carcinomas (Schmidt et al., 1997; Olivero et al., 1999) , showing the link between the MET gene and cancer. The role of the MET gene in breast cancer is more controversial, although MET protein expression is elevated in a fraction of tumours and over-expression has been detected in the invading front of human breast carcinomas (Tuck et al., 1996) .
The human RON gene is expressed in a number of epithelial cells and in lineages of hematopoietic origin (such as granulocytes and monocytes) (Gaudino et al., 1994) . Constitutive activation of the RON kinase (obtained by replacement of the RON extracellular domain with a protein dimerization motif) induces a motile-invasive phenotype, characterized by constitutive cell dissociation,`scattering', invasion of extracellular matrices and formation of aberrant tubular structures in vitro (Santoro et al., 1996) . Moreover, the introduction in the RON kinase of point mutations that activate the MET gene in human renal cell carcinoma releases the oncogenic and metastatic potential of the RON receptor (Santoro et al., 1998) .
In human breast cancer we have shown a remarkable increased expression of the RON gene (Maggiora et al., 1998) . This receptor expression mediates an invasive responses of breast cancer cells to ligand. This prompted us to identify the RON/stk homologue gene in cats and to study its expression in FMC.
To identify stk-like sequences in cats, we compared the coding sequences of the human RON and mouse stk gene. Strong homologies have been described among tyrosine kinase receptors of the same family in dierent species (Hanks et al., 1988) . Human RON and mouse stk genes show evident homology not only in the region encoding the kinase domain, as previously reported (Iwama et al., 1994; Ronsin et al., 1993) , but also in short (up to 20 bp long) sequences of the transmembrane and of the¯anking juxtamembrane domains ( Figure 1 ). The latter sequences are encoded by exons 11 ± 14 and 11 ± 13 in human and mouse gene, respectively. As the RON/stk tyrosine kinase domain showed also homologies with other kinase receptors, we selected an exon region that also diers greatly from the corresponding MET gene sequences in mice and humans (Ronsin et al., 1993; Iwama et al., 1994) . This is the sequence of human exon 11, on which primers were designed to amplify feline stk-like genomic DNA by PCR. Primers are boldfaced and italicized in Figure 1 . We directly sequenced the PCR product obtained. The obtained feline sequence ( Figure  1) showed stronger homology to the mouse stk exon 11. To amplify a longer region, a feline-speci®c sequence in exon 11 was used as sense primer and was coupled to an antisense primer designed according to the mouse stk exon 13 sequence, highly homologous to the human RON exon 14. Primers used are shown in Figure 1 (boldfaced). The PCR product was directly sequenced. Figure 1 shows the complete f-stk exonintron DNA sequence that we obtained, corresponding to the human RON exons 11 ± 14 and to the mouse stk 11 ± 13 exons. In fact, in the mouse stk the sequence corresponding to the human exon 13 is intronic. The comparison of the cat, man (Angeloni et al., 2000) and mouse (Waltz et al., 1998) DNA sequences in this region showed 88% homology between cat and man and 64% homology between mouse and cat. From the sequencing of the f-stk cDNA feline intron-exon boundaries were de®ned. In f-stk there is an exon, absent in the mouse gene and shorter than the human one, and thus partially corresponding to the human exon 13 (Figure 1) . The homologies between exonintron boundary sequences of f-stk and human and mouse genes also suggest that we have isolated the major f-stk transcript.
Primers identi®ed in putative exons 11 and 14 of the feline DNA sequence (numbered according to the homology to human RON) were used to amplify cDNA from retro-transcribed total RNA isolated from cat mammary tumours and tissues. Expression of f-stk was ®rst analysed in some non-neoplastic tissues, including spleen, lung and ovary (data not shown). As a positive control in subsequent RT ± PCR experiments cat lung RNA was used, while spleen RNA was used as a negative control. A low level of f-stk gene expression was found also in the ovary (data not shown).
Eight cat in®ltrating mammary adenocarcinomas and one synchronous FMC skin metastasis were harvested and snap frozen at surgery. Expression of f-stk transcripts was evaluated with RT ± PCR. As shown in Figure 2 , f-stk-speci®c sequences were found in 7/8 tumours and in the metastasis (sample 12 which is the synchronous metastasis of the primary tumour numbered 11). As a limited amount of cat mammary carcinoma tissues was available for either RNA or protein extraction, expression of the f-stk protein in carcinomas was surveyed in 34 archival samples using immunohistochemisty. This series included all the samples analysed in RT ± PCR. The study was carried out using anti-human RON antibodies selected for their ability to recognize a RON/stk-speci®c protein sequence in cat tissues. As the human RON receptor and its mouse homologue stk show a strong homology in the COOH terminal tail, we ®rst tested poly-and monoclonal antibodies directed against the human RON 20 amino acid COOH terminal sequence in Western blot analysis. Total protein extracts were prepared from two mammary tumour samples found positive in the RT ± PCR screening for the expression of f-stk (samples 5 and 6 of Figure 2 ) and from one sample not analysed by RT ± PCR (n.14). Proteins were separated under reducing conditions in SDS ± PAGE gels. As shown in Figure 3a , a polyclonal antibody (C-20, Santa Cruz Biotech) labelled a speci®c band of the approximate MW of 135 kD. This protein labelling was abrogated by the previous incubation of Having shown its speci®city, the antibody was used in immuno-histochemical survey of 34 archival cat mammary tumours. Cat mammary tumours are more commonly adenocarcinomas, with either solid, lobular or papillary features. The 34 tumours examined were all in®ltrating adenocarcinomas displaying dierent features classi®ed according to the most pronounced histological dierentiation as follows: ®ve papillary, 12 solid and 17 tubular. Ten out of 34 FMCs tested showed a multifocal positive staining distributed as a diuse cytoplasmic and/or membrane labelling of tumour cells (Figure 4) . These ten showed the following histological features: two were papillary, four solid and four tubular FMCs. One of the negative Although staining intensity was not semi-quantitatively scored, we noticed that the labelling was more intense in neoplastic cells at the periphery of the tumour mass (Figure 4) . The immuno-histochemical detection of membrane labelling in tumours was displaced by the pre-incubation with the speci®c peptide (data not shown). The remaining 24 tumours were scored either weakly positive or negative. Five out of eight carcinomas examined with RT ± PCR were scored, the other three being weakly positive or negative in immuno-histochemical analysis. Due to the expected lower anity of the antibody raised towards the human sequence, weak positivity cannot be easily weighed. Non-neoplastic glands were negative (not shown). Among the normal tissues examined with RT ± PCR, only the normal lung showed a weak positivity (data not shown).
In this study we describe for the ®rst time the expression of a tyrosine kinase oncogene in feline mammary cancer at RNA and protein level. MET family receptors in cats have not yet been described. A factor homologue to the human HGF (the MET ligand) has been cloned and found expressed in the cat liver; cat HGF showed more than 90% sequence and structure homology to human HGF (Kobayashi et al., 2001) . This suggests that the receptors of the MET family and growth factors of the HGF family might play an analogous role in human and cat tissues physiology and pathology.
In FMC we found the consistent expression of the f-stk gene, which is homologous to the RON gene overexpressed in human breast cancer (Maggiora et al., 1998) . RON belongs to the MET family of tyrosine kinase receptor genes. A number of reports suggest that members of this family are involved in the onset and progression of cancer. A direct link between the MET gene and cancer was demonstrated by germline and somatic missense mutations found in hereditary papillary renal cell carcinomas (Schmidt et al., 1997; Olivero et al., 1999) . Although no transforming counterpart of the RON gene has been identi®ed so far, constitutive activation of the RON kinase elicits a motogenic-invasive phenotype (Maggiora et al., 1998 ; Figure 2 Expression of f-stk in cat mammary tumours. RT ± PCR products of the predicted sizes were generated using primers designed on the sequence boldfaced in Figure 1 . Numbers on the top of each line indicate dierent samples. Lung tissue was used as a positive control (C+); b is the negative control. To demonstrate mRNA integrity, ampli®cation of cat p53 cDNA is shown, as the latter have been previously identi®ed in mammary tumours. One mg of total RNA was reverse transcribed using oligo dT primers in a reaction containing M-MLV-Reverse Transcriptase. The PCR reaction was performed using Taq Gold DNA polymerase (Perkin Elmer) using 30 pmol each of the sense and antisense primers. PCR conditions were as follows: 10' 958C; 1' 958C, 1' 568C, 1' 728C 30 cycles, 7' 728C. PCR products were puri®ed from agarose gel and directly sequenced (forward and reverse) Figure 3 Expression of the f-stk protein in cat mammary tumours studied with Western blot analysis. Proteins were labelled with rabbit polyclonal Ig against the human RON receptor (a) or with the same antibody in the presence of the peptide used for immunization of rabbits (b). T47D human breast cancer cells were used as positive control and the RON protein was identi®ed in total protein extract (tot) and after immunoprecipitation (ip). The arrows point to the 150 kDa b chain of the human RON (right), and to the 135 kDa f-stk putative b chain (left). Numbers on the top of each lane indicate dierent tumour samples. Proteins were extracted in buer containing Triton X-100 and protease inhibitors. Two mg of total protein were immunoprecpitated. Otherwise, 200 mg of total proteins were loaded onto SDS ± PAGE gels. In both Western blotting and immunoprecipitation the anti-RON polyclonal antibody (C-20, Santa Cruz Biotech.) was used. Blots were incubated with proteinA horseradish peroxidase (Amersham) and developed with Chemiluminescence kit (ECL, Amersham). The antibody neutralization was performed by previously incubating the antibody with a 12-fold excess amount (by weight) of blocking peptide for 2 h at room temperature Santoro et al., 1996) . In human breast cancer, receptors of the MET family have been studied. As already mentioned, we have shown that the RON gene is overexpressed (Maggiora et al., 1998) more than 20-fold in 20% of the cases. Notably, we found that the RON protein is only barely detectable in epithelial cells of the human mammary gland. In human breast carcinomas cells grown in vitro, activation of the RON receptor resulted in proliferation, migration and invasion through reconstituted basement membranes. Altogether, these data suggested a role for the RON gene in progression of human breast carcinomas to the invasive-metastatic phenotype.
Feline carcinomas are highly aggressive. Approximately 90% of feline mammary tumours are malignant, growing rapidly and metastasizing to regional lymph nodes and to lung, as the most malignant tumours in humans. The survival rate of FMC at ®rst post-surgical year is about 50% (for a review see Castagnaro et al., 1998c) . Recently, proliferation indexes (Castagnaro et al., 1998b,c) and tumour grading (Castagnaro et al., 1998a) have been correlated to aggressiveness in FMC. The majority of FMC are classi®ed as tubular, papillary and solid adenocarcinomas (Castagnaro et al., 1998a) like the human ones. Also scirrhous and anaplastic carcinomas are seen, but with a relatively low frequency. Most FMC express low level of hormone receptors and all of them do not respond to adjuvant anti-hormone therapy, as the more aggressive human breast carcinomas (Hamilton et al., 1976; Johnston et al., 1984) . Altogether, these data suggested that feline mammary carcinoma represent a valid model of very aggressive human breast carcinomas. In this context, it is not surprising that a member of the MET gene family is expressed at very high level in a consistent fraction of feline mammary carcinomas.
In conclusion, these data support the idea that spontaneous tumours in cats are appropriate for studying mammary cancer biology and suggest that pet population is a vastly underutilized resource of animal model. Dogs and cats develop spontaneous tumours with histopathologic and biologic behaviour similar to tumours that occur in humans. In addition, naturally occurring tumours in pet animals develop twice as frequently as in man and progress at a more rapid rate than in man. As feline mammary carcinomas respond, but minimally, to chemotherapy, they could be a valid model system available for testing innovative cancer therapeutic agents. Membrane and cytoplasmic staining is distributed multifocally in a tubular structure at higher magni®cation. 4006. Four mm sections of tissues in buered formalin and paran embedded were de-paranized by standard procedures and treated in a 0.1% hydrogen peroxide-methanol solution to block endogenous peroxidase activity. Sections were incubated with RON polyclonal antibody (Santa Cruz) overnight at room temperature, followed by incubation with avidin-biotin-peroxidase complex (ABC, Vector Labs) for 30 mins. After incubation with a solution of 0.01% diaminobenzidine and hydrogen peroxide for 5 min, sections were counterstained with haematoxylin
